^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
CANCER:

Malignant Pleural Mesothelioma

Related cancers:
Phase 2
Alliance for Clinical Trials in Oncology
Recruiting
Last update posted :
02/20/2024
Initiation :
03/14/2023
Primary completion :
12/15/2024
Completion :
12/15/2024
PD-L1 • ALK
|
Opdivo (nivolumab) • Yervoy (ipilimumab)
Phase 2
M.D. Anderson Cancer Center
Recruiting
Last update posted :
02/09/2024
Initiation :
08/05/2022
Primary completion :
04/01/2025
Completion :
04/01/2025
MSI
|
MSI-H/dMMR
|
vudalimab (XmAb717)
Phase 1
National Cancer Institute (NCI)
Not yet recruiting
Last update posted :
02/01/2024
Initiation :
02/06/2024
Primary completion :
12/18/2024
Completion :
12/18/2024
MSLN
|
MSLN expression • MSLN positive
|
LMB-100
Phase 1
University of Pennsylvania
Active, not recruiting
Last update posted :
01/24/2024
Initiation :
04/06/2017
Primary completion :
03/01/2025
Completion :
03/01/2025
PD-L1
|
MSLN expression
|
cyclophosphamide • fludarabine IV • TmMSTN-01
Phase 1
National Cancer Institute (NCI)
Active, not recruiting
Last update posted :
01/24/2024
Initiation :
08/25/2021
Primary completion :
12/31/2024
Completion :
12/31/2024
HER-2 • ER • PGR
|
HER-2 negative
|
cisplatin • gemcitabine • elimusertib (BAY 1895344) • liposomal gemcitabine (FF-10832)
Phase 2
Swiss Group for Clinical Cancer Research
Active, not recruiting
Last update posted :
01/17/2024
Initiation :
03/17/2021
Primary completion :
05/01/2024
Completion :
05/01/2024
CD4
|
Tecentriq (atezolizumab) • gemcitabine
Phase 1/2
National Cancer Institute (NCI)
Active, not recruiting
Last update posted :
01/10/2024
Initiation :
10/04/2018
Primary completion :
07/08/2023
Completion :
09/21/2024
PD-L1 • MSLN
|
PD-L1 expression • MSLN expression
|
Keytruda (pembrolizumab) • anetumab ravtansine (BAY 94-9343) • Pembroria (pembrolizumab biosimilar)
Phase 1/2
TCR2 Therapeutics
Active, not recruiting
Last update posted :
12/21/2023
Initiation :
06/21/2022
Primary completion :
11/28/2023
Completion :
12/01/2027
MSLN
|
MSLN expression • MSLN positive
|
cyclophosphamide • fludarabine IV • TC-510
Phase 3
PrECOG, LLC.
Active, not recruiting
Last update posted :
12/01/2023
Initiation :
02/18/2021
Primary completion :
04/01/2025
Completion :
12/01/2025
PD-L1
|
Opdivo (nivolumab) • cisplatin • Yervoy (ipilimumab) • carboplatin • Imfinzi (durvalumab) • pemetrexed
Phase 1
Ascentage Pharma Group Inc.
Recruiting
Last update posted :
11/21/2023
Initiation :
05/27/2019
Primary completion :
01/01/2025
Completion :
02/01/2025
ALK • ROS1
|
ALK positive • ROS1 fusion • ROS1 positive • ALK-ROS1 fusion
|
APG-2449
Phase 1/2
University Hospital, Antwerp
Recruiting
Last update posted :
11/09/2023
Initiation :
02/24/2023
Primary completion :
10/01/2026
Completion :
10/01/2026
WT1
|
cisplatin • Tecentriq (atezolizumab) • carboplatin • pemetrexed
Phase 2
M.D. Anderson Cancer Center
Active, not recruiting
Last update posted :
10/13/2023
Initiation :
03/03/2017
Primary completion :
06/30/2024
Completion :
06/30/2024
CD4
|
Avastin (bevacizumab) • cisplatin • Tecentriq (atezolizumab) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • Vasforda (bevacizumab biosimilar)
Phase 2
Fundación GECP
Recruiting
Last update posted :
09/07/2023
Initiation :
09/20/2021
Primary completion :
03/30/2025
Completion :
04/30/2025
CD4
|
bintrafusp alfa (M7824)
Phase 1
Memorial Sloan Kettering Cancer Center
Recruiting
Last update posted :
08/09/2023
Initiation :
09/30/2020
Primary completion :
09/01/2024
Completion :
09/01/2024
MSLN
|
MSLN expression
|
cyclophosphamide • ATA2271 • engineered autologous T cells
Phase 1
Memorial Sloan Kettering Cancer Center
Active, not recruiting
Last update posted :
08/02/2023
Initiation :
07/24/2019
Primary completion :
07/01/2024
Completion :
07/01/2024
WT1
|
Opdivo (nivolumab) • Zeltherva (galinpepimut-S) • Leukine (sargramostim)
Phase 1/2
Memorial Sloan Kettering Cancer Center
Active, not recruiting
Last update posted :
07/04/2023
Initiation :
05/01/2015
Primary completion :
04/30/2024
Completion :
04/30/2024
PD-L1 • MSLN
|
MSLN expression
|
Keytruda (pembrolizumab) • cyclophosphamide • iCasp9M28z T cell infusion
Phase 3
Bristol-Myers Squibb
Completed
Last update posted :
07/04/2023
Initiation :
11/29/2016
Primary completion :
03/25/2020
Completion :
05/30/2023
PD-L1
|
PD-L1 expression
|
Opdivo (nivolumab) • cisplatin • Yervoy (ipilimumab) • carboplatin • pemetrexed
Phase 1/2
NuCana plc
Recruiting
Last update posted :
06/23/2023
Initiation :
03/08/2023
Primary completion :
08/01/2024
Completion :
01/01/2025
MSI
|
Keytruda (pembrolizumab) • docetaxel • fosifloxuridine nafalbenamide (NUC-3373) • levoleucovorin calcium
Phase 2
Translational Research in Oncology
Withdrawn
Last update posted :
06/07/2023
Initiation :
04/30/2023
Primary completion :
04/30/2025
Completion :
04/30/2025
MSI
|
MSI-H/dMMR
|
Tevimbra (tislelizumab) • Stivarga (regorafenib)
Phase 1
Roswell Park Cancer Institute
Recruiting
Last update posted :
06/02/2023
Initiation :
03/10/2022
Primary completion :
03/15/2025
Completion :
03/15/2025
PD-L1
|
PD-L1 expression
|
Photofrin (porfimer sodium)
Phase 1/2
TCR2 Therapeutics
Recruiting
Last update posted :
05/09/2023
Initiation :
04/15/2019
Primary completion :
07/01/2024
Completion :
04/01/2026
MSLN
|
MSLN expression • MSLN positive
|
Opdivo (nivolumab) • Yervoy (ipilimumab) • cyclophosphamide • gavocabtagene autoleucel (TC-210) • fludarabine IV
Phase 2
University of Chicago
Active, not recruiting
Last update posted :
04/28/2023
Initiation :
03/31/2015
Primary completion :
03/20/2024
Completion :
03/20/2024
PD-L1
|
PD-L1 expression
|
Keytruda (pembrolizumab)
Phase 1/2
Institut Bergonié
Recruiting
Last update posted :
03/03/2023
Initiation :
05/04/2018
Primary completion :
12/31/2024
Completion :
12/31/2025
PD-L1 • BRAF • ALK • TMB • MSI • ROS1 • CTLA4
|
TMB-H • ALK positive • ALK mutation • ROS1 positive
|
Bavencio (avelumab) • Stivarga (regorafenib)
Phase 2
The Netherlands Cancer Institute
Recruiting
Last update posted :
01/16/2023
Initiation :
03/01/2021
Primary completion :
12/05/2024
Completion :
12/05/2024
CTLA4
|
Keytruda (pembrolizumab) • cisplatin • Lenvima (lenvatinib)
Phase 2
Baylor College of Medicine
Completed
Last update posted :
09/29/2022
Initiation :
05/11/2016
Primary completion :
08/06/2019
Completion :
09/01/2022
PD-L1 • CD8 • CD4 • ICOS
|
PD-L1 expression
|
Imfinzi (durvalumab) • Imjudo (tremelimumab)
Phase N/A
Armando Santoro, MD
Completed
Last update posted :
09/10/2022
Initiation :
11/01/2012
Primary completion :
12/01/2016
Completion :
12/01/2017
BRCA1 • TUBB3
|
BRCA1 expression • TUBB3 expression
|
vinorelbine tartrate
Phase 3
ETOP IBCSG Partners Foundation
Completed
Last update posted :
08/24/2022
Initiation :
09/12/2017
Primary completion :
02/20/2019
Completion :
11/30/2021
PD-L1
|
Keytruda (pembrolizumab) • gemcitabine • vinorelbine tartrate
Phase N/A
Sohag University
Recruiting
Last update posted :
02/08/2022
Initiation :
02/01/2022
Primary completion :
06/01/2022
Completion :
12/01/2022
GPC1
|
GPC1 expression
Phase 2
Wales Cancer Trials Unit
Completed
Last update posted :
10/12/2021
Initiation :
03/01/2016
Primary completion :
03/17/2021
Completion :
03/17/2021
BRCA1
|
vinorelbine tartrate • Navelbine oral (vinorelbine tartrate oral)
Phase 2
University of Zurich
Completed
Last update posted :
09/29/2021
Initiation :
11/01/2012
Primary completion :
12/01/2019
Completion :
08/01/2021
CDKN1A
|
cisplatin
Phase 2
Intergroupe Francophone de Cancerologie Thoracique
Completed
Last update posted :
02/10/2021
Initiation :
03/24/2016
Primary completion :
02/01/2018
Completion :
06/22/2019
PD-L1
|
PD-L1 expression
|
Opdivo (nivolumab) • Yervoy (ipilimumab)
Phase 2
Istituto Clinico Humanitas
Completed
Last update posted :
01/22/2021
Initiation :
11/01/2014
Primary completion :
12/01/2015
Completion :
12/01/2017
KIT • PDGFRB
|
gemcitabine • imatinib • pemetrexed
Phase 1/2
Armando Santoro, MD
Completed
Last update posted :
01/22/2021
Initiation :
01/01/2013
Primary completion :
05/01/2016
Completion :
12/01/2017
MET • HGF
|
MET expression
|
carboplatin • pemetrexed • tivantinib (ARQ 197)
Phase 1
Mayo Clinic
Completed
Last update posted :
01/11/2021
Initiation :
11/01/2011
Primary completion :
04/11/2019
Completion :
04/11/2019
CD4
|
MV-NIS
Phase 2
Bayer
Completed
Last update posted :
11/04/2020
Initiation :
12/03/2015
Primary completion :
05/31/2017
Completion :
09/06/2019
MSLN
|
MSLN expression
|
pemetrexed • vinorelbine tartrate • anetumab ravtansine (BAY 94-9343)
Phase 1b
Aduro Biotech, Inc.
Completed
Last update posted :
09/30/2020
Initiation :
09/03/2014
Primary completion :
09/05/2018
Completion :
08/19/2019
MSLN
|
cisplatin • cyclophosphamide • pemetrexed • CRS-207
Phase N/A
Memorial Sloan Kettering Cancer Center
Completed
Last update posted :
07/01/2020
Initiation :
01/01/2013
Primary completion :
06/30/2020
Completion :
06/30/2020
BAP1
|
BAP1 mutation